CN104661663A - 用于眼部疾病和病症的组合物和治疗 - Google Patents

用于眼部疾病和病症的组合物和治疗 Download PDF

Info

Publication number
CN104661663A
CN104661663A CN201380039713.2A CN201380039713A CN104661663A CN 104661663 A CN104661663 A CN 104661663A CN 201380039713 A CN201380039713 A CN 201380039713A CN 104661663 A CN104661663 A CN 104661663A
Authority
CN
China
Prior art keywords
progesterone
compositions
patient
eyelid
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380039713.2A
Other languages
English (en)
Chinese (zh)
Inventor
常伟伟
肯尼斯·索耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhodes Technologies Inc
Original Assignee
Rhodes Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Technologies Inc filed Critical Rhodes Technologies Inc
Priority to CN201710063950.2A priority Critical patent/CN107595857A/zh
Publication of CN104661663A publication Critical patent/CN104661663A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CN201380039713.2A 2012-07-27 2013-07-26 用于眼部疾病和病症的组合物和治疗 Pending CN104661663A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710063950.2A CN107595857A (zh) 2012-07-27 2013-07-26 用于眼部疾病和病症的组合物和治疗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261676530P 2012-07-27 2012-07-27
US61/676,530 2012-07-27
US201361756321P 2013-01-24 2013-01-24
US61/756,321 2013-01-24
PCT/US2013/052264 WO2014018856A1 (en) 2012-07-27 2013-07-26 Compositions and treatment for eye diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710063950.2A Division CN107595857A (zh) 2012-07-27 2013-07-26 用于眼部疾病和病症的组合物和治疗

Publications (1)

Publication Number Publication Date
CN104661663A true CN104661663A (zh) 2015-05-27

Family

ID=49997851

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380039713.2A Pending CN104661663A (zh) 2012-07-27 2013-07-26 用于眼部疾病和病症的组合物和治疗
CN201710063950.2A Pending CN107595857A (zh) 2012-07-27 2013-07-26 用于眼部疾病和病症的组合物和治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710063950.2A Pending CN107595857A (zh) 2012-07-27 2013-07-26 用于眼部疾病和病症的组合物和治疗

Country Status (20)

Country Link
US (2) US20150216877A1 (cg-RX-API-DMAC7.html)
EP (1) EP2877184B1 (cg-RX-API-DMAC7.html)
JP (1) JP6209777B2 (cg-RX-API-DMAC7.html)
KR (1) KR102097663B1 (cg-RX-API-DMAC7.html)
CN (2) CN104661663A (cg-RX-API-DMAC7.html)
AU (1) AU2013295645B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015001847A8 (cg-RX-API-DMAC7.html)
CA (1) CA2880027C (cg-RX-API-DMAC7.html)
DK (1) DK2877184T3 (cg-RX-API-DMAC7.html)
ES (1) ES2759781T3 (cg-RX-API-DMAC7.html)
HU (1) HUE046963T2 (cg-RX-API-DMAC7.html)
IL (1) IL236920B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00542A (cg-RX-API-DMAC7.html)
MX (1) MX362185B (cg-RX-API-DMAC7.html)
NZ (1) NZ704247A (cg-RX-API-DMAC7.html)
PL (1) PL2877184T3 (cg-RX-API-DMAC7.html)
PT (1) PT2877184T (cg-RX-API-DMAC7.html)
SM (1) SMT201900678T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014018856A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500561B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9682032B2 (en) 2013-03-15 2017-06-20 Glia, Llc Cranial delivery of pharmaceuticals
WO2015080758A1 (en) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
WO2016014419A1 (en) 2014-07-21 2016-01-28 Glia, Llc Method for treating radiotherapy-and-chemotherapy associated cognitive or emotional impairment with cannabinoids
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR101960023B1 (ko) * 2016-12-21 2019-03-20 김보경 이산화탄소 발생 장치
WO2021163253A1 (en) * 2020-02-12 2021-08-19 Glia, Llc Progesterone combinations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102656A (en) 1983-07-29 1992-04-07 The Mennen Company Antiperspirant creams
US4937069A (en) 1985-11-15 1990-06-26 Bristol-Myers Squibb Company Anhydrous semi-solid antiperspirant suspension
US5069897A (en) 1987-10-16 1991-12-03 The Proctor & Gamble Company Antiperspirant creams
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7572780B2 (en) * 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
WO2009046967A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
CN101757622A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 一种眼部抗炎的药物组合物
US8871184B2 (en) * 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions

Also Published As

Publication number Publication date
EP2877184B1 (en) 2019-09-04
NZ704247A (en) 2018-04-27
BR112015001847A2 (pt) 2017-07-04
CN107595857A (zh) 2018-01-19
DK2877184T3 (da) 2019-12-09
US20170189413A1 (en) 2017-07-06
IN2015DN00542A (cg-RX-API-DMAC7.html) 2015-06-26
KR20150038311A (ko) 2015-04-08
KR102097663B1 (ko) 2020-04-06
JP6209777B2 (ja) 2017-10-11
US20150216877A1 (en) 2015-08-06
CA2880027C (en) 2021-12-07
US9925201B2 (en) 2018-03-27
HUE046963T2 (hu) 2020-04-28
MX2015001250A (es) 2015-10-22
PT2877184T (pt) 2019-12-02
JP2015524434A (ja) 2015-08-24
BR112015001847A8 (pt) 2021-09-08
EP2877184A1 (en) 2015-06-03
CA2880027A1 (en) 2014-01-30
EP2877184A4 (en) 2016-03-30
ES2759781T3 (es) 2020-05-12
SMT201900678T1 (it) 2020-03-13
AU2013295645A1 (en) 2015-02-05
HK1210968A1 (en) 2016-05-13
AU2013295645B2 (en) 2017-08-24
IL236920B (en) 2018-06-28
WO2014018856A1 (en) 2014-01-30
PL2877184T3 (pl) 2020-04-30
MX362185B (es) 2019-01-08
ZA201500561B (en) 2016-04-28

Similar Documents

Publication Publication Date Title
US9925201B2 (en) Compositions and treatment for eye diseases and disorders
US20240245625A1 (en) Opthalmic compositions comprising f6h8
Chang et al. Phase II results of an intraocular steroid delivery system for cataract surgery
US20140113889A1 (en) Treatment for dry eye
US20210046022A1 (en) Formulations for the treatment of ocular surface diseases and related methods
CN111372564B (zh) 用于治疗眼周分泌腺中或眼表上的异常发炎的组合物和方法
TWI632913B (zh) 用於眼部疾病或異常之組合物及其治療方法
EP2424535B1 (en) Methods and compositions for treating dry eye
HK1210968B (en) Compositions and treatment for eye diseases and disorders
CA3076567C (en) Ophthalmic compositions comprising f6h8
US20140274985A1 (en) Systemic administration of androgen in treating dry eye syndrome
CN105214092B (zh) 重组人白细胞介素-1受体拮抗剂及其组合物及药物用途
WO2022123597A1 (en) Apremilast ophthalmic compositions
KR20240130701A (ko) 알라닐-글루타민 및 알라닐-글루타민을 포함하는 안과용 조성물의 새로운 용도
HK40028751A (en) Ophthalmic compositions comprising f6h8
HK40031764B (zh) 用於治疗眼周分泌腺中或眼表上的异常发炎的组合物和方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150527